Join us for a focused, practical session that breaks down how to conduct high-quality feasibility assessments (FAs) that support robust evidence synthesis, that meets diverse HTA markets. Drawing from guidance across leading HTA bodies including CADTH, EU HTA CG and IQWiG, introducing step-by-step tools and visualization techniques to help you plan with greater clarity, reduce uncertainty, and align internal teams more effectively.
Why Attend:
With increasing complexity in HTA expectations across regional to national bodies, pharma teams need to confidently navigate an array of indirect treatment comparison choices. Submissions often face criticism when methods are poorly justified, with poor documentation of decisions. This session will equip you to anticipate methodological challenges and tailor strategies to international and national expectations.
Key Takeaways:
Global Feasibility Checklist: A practical guide to feasibility assessment, harmonizing key elements from international HTA guidance, ensuring you're designing for success from day one.
Feasibility Reporting Checklist: A clear, transparent structure for documenting your decision-making process, supporting internal alignment and external HTA scrutiny.
Visualization for Better Decisions: Learn how evidence mapping, network diagrams, and trial matrices can simplify complexity, support stakeholder engagement, and highlight gaps early in the process.
Bonus:
Attendees will receive the Global Feasibility Assessment Checklist and a sample visualization toolkit to apply directly in their next project.
Date: 18th June 2025
Time: 8am ET | 1pm BST | 2pm CEST
Speaker
Maria Rizzo, Head of Evidence Synthesis at GIPAM. A strategic advisor in evidence synthesis and market access, with a focus on helping pharma clients streamline feasibility assessments and prepare evidence strategies that withstand global scrutiny.
